Cleveland Clinic Tall Rounds^®:
Caring for Your Patients with ATTR

Early diagnosis and intervention for transthyretin amyloidosis (ATTR) is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part of clinicians. Therapeutic options are limited, but there are new and emerging agents and emerging indications with which clinicians may not be familiar. Access to specialized care centers is limited for many patients, leading to suboptimal management and disease monitoring. This education fills a significant need for healthcare team education to ensure all patients benefit from best-practices in recognizing, diagnosing, and managing amyloidosis. Learn More about the Cleveland Clinic Amyloidosis Center

Webcasts

Post‐diagnostic Monitoring of Cardiac Amyloidosis
Faculty: Andres Carmona Rubio, MD, Alvin George, MD, Mazen Hanna, MD, Mohammed Kanj, MD, Deborah Kwon, MD

Release date: August 28, 2024
Expiration date: August 27, 2026
Estimated Time: 1 hour

Type:  Webcast
Technical Requirements: None
Specialty: Cardiology, Neurology and Primary Care

Treating Confirmed ATTR
Faculty: Andres Carmona Rubio, MD, Arianne Clare C. Agdamag, MD, Mazen Hanna, MD, Jack Khouri, MD, Trejeeve Martyn, MD, MSc, Preethi William, MD

Release date: April 30, 2024
Expiration date: April 29, 2026
Estimated Time: 1 hour

Type:  Webcast
Technical Requirements: None
Specialty: Cardiology, Neurology and Primary Care

Contemporary Strategies: Diagnosing ATTR Amyloidosis
Faculty: Bryan Abadie, MD, Jeremy Brooksbank, MD, Andres Carmona Rubio, MD, Mazen Hanna, MD, Deborah Kwon, MD, Jason Valent, MD,

Release date: October 30, 2023
Expiration date: October 29, 2025
Estimated Time: 1 hour

Type:  Webcast
Technical Requirements: None
Specialty: Cardiology, Neurology and Primary Care

Target Audience

This online series is designed for physicians, allied health practitioners and students interested in complex cardiovascular and thoracic conditions and those who care for patients with ATTR.

Acknowledgment

The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:

Alexion Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

AstraZeneca Pharmaceuticals

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, The France Foundation, and Cleveland Clinic’s Heart, Vascular and Thoracic Institute.

For further information about this activity, contact Katie Breznai at [email protected]